Related references
Note: Only part of the references are listed.Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier
Garima Sharma et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms
Helene F. E. Gleitz et al.
EMBO MOLECULAR MEDICINE (2018)
Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain
Belletti Daniela et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature
J. Perez-Lopez et al.
MOLECULAR GENETICS AND METABOLISM (2018)
A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II
Hiroyuki Sonoda et al.
MOLECULAR THERAPY (2018)
Blood-Brain Delivery Methods Using Nanotechnology
Daniel Mihai Teleanu et al.
PHARMACEUTICS (2018)
Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer
Kanut Laoharawee et al.
HUMAN GENE THERAPY (2017)
Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model
Marika Salvalaio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A
Tilman Schuster et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
Joseph Muenzer et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry
Joseph Muenzer et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: Results from a single-center case series study
Jose Francisco da Silva Franco et al.
INTRACTABLE & RARE DISEASES RESEARCH (2017)
A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II
Joseph Muenzer et al.
GENETICS IN MEDICINE (2016)
Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice
Christian Hinderer et al.
HUMAN GENE THERAPY (2016)
Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders
Marika Salvalaio et al.
PLOS ONE (2016)
Nanoparticle transport across the blood brain barrier
Andreas M. Grabrucker et al.
TISSUE BARRIERS (2016)
Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice
Marta Valenza et al.
EMBO MOLECULAR MEDICINE (2015)
Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II
Sung Yoon Cho et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Insulin Receptor Antibody-Iduronate 2-Sulfatase Fusion Protein: Pharmacokinetics, Anti-Drug Antibody, and Safety Pharmacology in Rhesus Monkeys
Ruben J. Boado et al.
BIOTECHNOLOGY AND BIOENGINEERING (2014)
Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport
Giovanni Tosi et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years
Rosella Tomanin et al.
ORPHANET JOURNAL OF RARE DISEASES (2014)
Improvement of CNS Defects Via Continuous Intrathecal Enzyme Replacement by Osmotic Pump in Mucopolysaccharidosis Type II Mice
Young Bae Sohn et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2013)
Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II
Takashi Higuchi et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders
Janet Hsu et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2012)
CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
Pericles Calias et al.
PLOS ONE (2012)
Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II
A. Friso et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy
Vinicia Assunta Polito et al.
HUMAN MOLECULAR GENETICS (2010)
Gene therapy of Hunter syndrome: Evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS)
A. Friso et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2008)
Recognition and diagnosis of Mucopolysaccharidosis II (Hunter syndrome)
Rick Martin et al.
PEDIATRICS (2008)
The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome)
A. R. Garcia et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2007)
Targeting the central nervous system:: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123
G. Tosi et al.
JOURNAL OF CONTROLLED RELEASE (2007)
Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice
H. Fu et al.
GENE THERAPY (2007)
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)
Joseph Muenzer et al.
GENETICS IN MEDICINE (2006)
Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery
M Cardone et al.
HUMAN MOLECULAR GENETICS (2006)
Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts
A Friso et al.
JOURNAL OF GENE MEDICINE (2005)
A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease)
YV Voznyi et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2001)
Share Paper
